The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Preliminary results with the LSD1 inhibitor iadademstat combined with aza-ven in newly diagnosed AML
Curtis Lachowiez, MD, Oregon Health & Science University, Portland, OR, discusses the preliminary safety and efficacy results of a Phase Ib trial (NCT06357182) investigating the LSD1 inhibitor iadademstat in combination with azacitidine and venetoclax (aza-ven) in patients with newly diagnosed acute myeloid leukemia (AML). Dr Lachowiez notes that the study aims to determine if the triplet therapy can further improve outcomes, building on previous studies demonstrating activity of iadademstat with azacitidine and as monotherapy, and highlights the encouraging early findings. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
